BPC 157 vs Thymosin Beta 4
Evidence tier, human-evidence strength, regulatory status, and hype-vs-data — side by side.
On published evidence, Thymosin Beta 4 currently grades higher (D-tier vs D-tier). That reflects evidence maturity, not that it's “better” for any person or goal.
- Stronger human evidence: comparable
- More hype than data: neither stands out
| bpc-157 | thymosin-beta-4 | |
|---|---|---|
| Class | Tissue-repair peptides | Thymic & immune-modulating peptides |
| Regulatory status | Research-use-only | Research-use-only |
| Candidate sources | 0 | 0 |
| Top study types (candidate) | — | — |
| Translation risk | pending review | pending review |
BPC 157 vs Thymosin Beta 4: FAQ
Is BPC 157 better than Thymosin Beta 4?
On published evidence, Thymosin Beta 4 currently grades higher (D-tier vs D-tier). That reflects evidence maturity, not that it's “better” for any person or goal. Neither is a recommendation to use anything; this compares the state of the evidence only.
What's the difference between BPC 157 and Thymosin Beta 4?
BPC 157 is research-use-only and sits at the “Early human” evidence stage; Thymosin Beta 4 is research-use-only and sits at “Early human.”
Which has stronger human evidence, BPC 157 or Thymosin Beta 4?
Both have comparable human-evidence levels on our scale.
Research reference only. Not medical advice, treatment instructions, or a purchase recommendation. Consult a licensed professional.